Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because ...

Korro Bio (NASDAQ:KRRO) used its Analyst Day to outline the rationale and development plans for KRRO-121, an RNA-editing ...

After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...

Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. | Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not ...

Sanofi announced the signing of a share buyback mandate for up to €1 billion. Pfizer said its obesity injection, which was ...

While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study ...

Korro Bio ( (KRRO) ) has provided an announcement.

WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 ...

Researchers from the Faculty of Engineering at The University of Hong Kong (HKU) have developed two innovative deep-learning ...

GSK returns rights to Wave's RNA editing program for AATD; Cassidy took on RFK Jr. over vaccines. Now Kennedy's followers are ...

Detailed price information for Wave Life Sci Ord Sh (WVE-Q) from The Globe and Mail including charting and trades.

Ltd (NASDAQ:WVE) stock rose 2.1% Monday after the clinical-stage biotechnology company announced it has regained full rights to WVE-006, its investigational RNA editing therapy for alpha-1 antitrypsin ...